PDF(Pubmed)
Abstract：
Laryngeal human papillomavirus (HPV) infection causes recurrent respiratory papillomatosis (RRP) and accounts for up to 25% of laryngeal cancers. Lack of satisfactory preclinical models is one reason that treatments for these diseases are limited. We sought to assess the literature describing preclinical models of laryngeal papillomavirus infection.
PubMed, Web of Science, and Scopus were searched from the inception of database through October 2022.
Studies searched were screened by two investigators. Eligible studies were peer-reviewed, published in English, presented original data, and described attempted models of laryngeal papillomavirus infection. Data examined included type of papillomavirus, infection model, and results including success rate, disease phenotype, and viral retention.
After screening 440 citations and 138 full-text studies, 77 studies published between 1923 and 2022 were included. Models used low-risk HPV or RRP (n = 51 studies), high-risk HPV or laryngeal cancer (n = 16), both low- and high-risk HPV (n = 1), and animal papillomaviruses (n = 9). For RRP, 2D and 3D cell culture models and xenografts retained disease phenotypes and HPV DNA in the short term. Two laryngeal cancer cell lines were consistently HPV-positive in multiple studies. Animal laryngeal infections with animal papillomaviruses resulted in disease and long-term retention of viral DNA.
Laryngeal papillomavirus infection models have been researched for 100 years and primarily involve low-risk HPV. Most models lose viral DNA after a short duration. Future work is needed to model persistent and recurrent diseases, consistent with RRP and HPV-positive laryngeal cancer.
NA Laryngoscope, 133:3256-3268, 2023.
PubMed, Web of Science, and Scopus were searched from the inception of database through October 2022.
Studies searched were screened by two investigators. Eligible studies were peer-reviewed, published in English, presented original data, and described attempted models of laryngeal papillomavirus infection. Data examined included type of papillomavirus, infection model, and results including success rate, disease phenotype, and viral retention.
After screening 440 citations and 138 full-text studies, 77 studies published between 1923 and 2022 were included. Models used low-risk HPV or RRP (n = 51 studies), high-risk HPV or laryngeal cancer (n = 16), both low- and high-risk HPV (n = 1), and animal papillomaviruses (n = 9). For RRP, 2D and 3D cell culture models and xenografts retained disease phenotypes and HPV DNA in the short term. Two laryngeal cancer cell lines were consistently HPV-positive in multiple studies. Animal laryngeal infections with animal papillomaviruses resulted in disease and long-term retention of viral DNA.
Laryngeal papillomavirus infection models have been researched for 100 years and primarily involve low-risk HPV. Most models lose viral DNA after a short duration. Future work is needed to model persistent and recurrent diseases, consistent with RRP and HPV-positive laryngeal cancer.
NA Laryngoscope, 133:3256-3268, 2023.
摘要：
目的：喉人乳头状瘤病毒（HPV）感染导致复发性呼吸道乳头状瘤病（RRP），占喉癌的25％。缺乏令人满意的临床前模型是这些疾病的治疗受到限制的原因之一。我们试图评估描述喉乳头状瘤病毒感染临床前模型的文献。
方法：PubMed，WebofScience,和Scopus从数据库开始到2022年10月进行了搜索。
方法：搜索的研究由两名研究者筛选。符合条件的研究进行了同行评审，以英文出版,提供原始数据，并描述了喉乳头状瘤病毒感染的尝试模型。检查的数据包括乳头瘤病毒的类型，感染模型,结果包括成功率，疾病表型，和病毒保留。
结果：在筛选了440篇引文和138篇全文研究后，纳入了1923年至2022年之间发表的77项研究。模型使用低风险HPV或RRP（n=51项研究），高危型HPV或喉癌（n=16），低危型和高危型HPV（n=1），和动物乳头瘤病毒(n=9)。对于RRP，2D和3D细胞培养模型和异种移植物在短期内保留了疾病表型和HPVDNA。在多项研究中，两种喉癌细胞系始终为HPV阳性。动物乳头瘤病毒的动物喉感染导致疾病和病毒DNA的长期保留。
结论：喉乳头状瘤病毒感染模型已经研究了100年，主要涉及低风险HPV。大多数模型在短时间内丢失病毒DNA。未来的工作需要对持续性和复发性疾病进行建模，与RRP和HPV阳性喉癌一致。
方法：N/A喉镜，2023年。
方法：PubMed，WebofScience,和Scopus从数据库开始到2022年10月进行了搜索。
方法：搜索的研究由两名研究者筛选。符合条件的研究进行了同行评审，以英文出版,提供原始数据，并描述了喉乳头状瘤病毒感染的尝试模型。检查的数据包括乳头瘤病毒的类型，感染模型,结果包括成功率，疾病表型，和病毒保留。
结果：在筛选了440篇引文和138篇全文研究后，纳入了1923年至2022年之间发表的77项研究。模型使用低风险HPV或RRP（n=51项研究），高危型HPV或喉癌（n=16），低危型和高危型HPV（n=1），和动物乳头瘤病毒(n=9)。对于RRP，2D和3D细胞培养模型和异种移植物在短期内保留了疾病表型和HPVDNA。在多项研究中，两种喉癌细胞系始终为HPV阳性。动物乳头瘤病毒的动物喉感染导致疾病和病毒DNA的长期保留。
结论：喉乳头状瘤病毒感染模型已经研究了100年，主要涉及低风险HPV。大多数模型在短时间内丢失病毒DNA。未来的工作需要对持续性和复发性疾病进行建模，与RRP和HPV阳性喉癌一致。
方法：N/A喉镜，2023年。
